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AbstrACt
Introduction Numerous longitudinal studies, systematic 
reviews and meta-analyses have examined psychiatric 
disorders as risk factors for the development of type 2 
diabetes mellitus. A more comprehensive overview of 
the area is warranted to summarise current evidence 
and discuss strengths and weaknesses to guide future 
research.
Aim The aim of this umbrella review is to determine 
whether and to what extent different psychiatric disorders 
are associated with the development of type 2 diabetes 
mellitus. Furthermore, the umbrella review also assesses 
the evidence on potential mediating mechanisms.
Methods and analysis The present umbrella review will 
consist of a comprehensive systematic search of published 
systematic reviews and meta-analyses of observational 
longitudinal studies investigating whether a psychiatric 
disorder is associated with the risk of developing type 2 
diabetes. PubMed, Embase, PsychINFO and the Cochrane 
Database of Systematic Reviews will be searched, and the 
results will be screened for inclusion by two independent 
reviewers. Furthermore, the reference lists of included 
publications will be manually searched. Two independent 
reviewers will extract data and assess the methodological 
quality in the included systematic reviews and meta-
analyses. Evidence on potential mediating mechanisms 
included in the systematic reviews and meta-analyses will 
also be reviewed. The implications of the overview will be 
discussed in light of the quality of the included studies, 
and suggestions for clinical practice and future research 
will be made.
Ethics and dissemination Ethical approval is not 
required for this umbrella review. Our review will be 
submitted for publication in a peer-reviewed international 
journal using open access option if available. The results 
will also be disseminated at international conferences.
PrOsPErO registration number CRD42018096362 
IntrOduCtIOn
Type two diabetes mellitus is a chronic meta-
bolic condition that is increasingly common 
worldwide.1 Nine in ten diabetes cases are 
diagnosed with type 2 diabetes.2 Several 
factors may contribute to the increase in 
the number of people with type 2 diabetes, 
including the ageing of populations,3 an 
increased number of people with a seden-
tary lifestyle,3 the global obesity epidemic,3 4 
and the increase in life expectancy.5 Further-
more, earlier and improved recognition of 
type 2 diabetes has increased in the number 
of people with diagnosed type 2 diabetes.3 
A recent narrative review summarised 
evidence on different mental health problems 
(including psychiatric diseases, but also forms 
of chronic stress) as risk factors for type 2 
diabetes.6 The review concluded that longitu-
dinal studies support an association of depres-
sion, anxiety, sleeping problems, ‘general 
emotional stress’, ‘anger’ and ‘hostility’ with 
increased risk of type 2 diabetes. Findings 
were mixed regarding ‘childhood neglect’, 
‘life events’ and ‘work stress’.6 More recently, 
de Jonge and colleagues studied cross-sec-
tional associations between 16 different Diag-
nostic and Statistical Manual of Mental Disorders 
(DSM)-IV psychiatric disorders and diabetes 
mellitus in over 52 000 adults.7 Depression, 
intermittent explosive disorder, binge eating 
disorder and bulimia nervosa were associ-
ated with increased risk of diabetes mellitus 
after adjustment for comorbidity.7 The type 
of diabetes was unknown and no temporal 
strengths and limitations of this study
 ► To our knowledge, this is the first protocol for an um-
brella review on psychiatric disorders as risk factors 
for type 2 diabetes.
 ► A broad search strategy will be used to ensure a 
comprehensive synthesis of existing systematic re-
views and meta-analyses in this area.
 ► The methodological quality of the included system-
atic reviews and meta-analyses will be assessed.
 ► Assessment of data extraction and methodolog-
ical quality will be performed by two independent 
reviewers.
 ► As in other umbrella reviews, the quality of the sum-
mary findings depends on the quality and content 
of the systematic reviews and meta-analyses that 
are available.
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inferences could be made due to the cross-sectional 
design.7
Several systematic reviews and meta-analyses have also 
investigated whether specific psychiatric disorders are 
associated with the risk of developing type 2 diabetes.8–13 
Mezuk et al, for example, included 13 prospective studies 
and found that depression was associated with a 1.6-fold 
increased risk of developing type 2 diabetes during a 
follow-up of 3.0–15.6 years.8 Based on 12 longitudinal 
studies, Smith et al found that people with a diagnosed 
anxiety disorder or elevated anxiety symptoms had a 
1.3-fold increased risk of developing type 2 diabetes.9 
Stubbs et al investigated 25 studies and concluded that 
people with schizophrenia had almost double the risk of 
developing type 2 diabetes compared with those without 
that psychiatric disorder.10 Furthermore, in two other 
meta-analyses of four and five studies, Vancampfort and 
colleagues found that people with bipolar disorder or 
post-traumatic stress disorder had a 1.5-fold increased risk 
of type 2 diabetes.11 12 A further meta-analysis on different 
eating disorders found bulimia nervosa being a risk factor 
for type 2 diabetes, whereas people with anorexia nervosa 
had a reduced risk of developing type 2 diabetes, and the 
association of binge eating disorder with type 2 diabetes 
was not statistically significant.13 However, an important 
limitation was the small number of included studies.13
Different psychiatric disorders may increase the risk 
of the development of type 2 diabetes through several 
pathways involving both behavioural and physiological 
mechanisms, including, for example, less healthy eating 
behaviours in terms of quality and quantity of food, phys-
ical inactivity, smoking and higher alcohol consumption.14 
These factors, in turn, are associated with an increased 
risk of type 2 diabetes.15 Furthermore, the pharmacolog-
ical treatment of various psychiatric disorders may affect 
type 2 diabetes risk.16 17 For example, the association 
between antipsychotic drug use and development of type 
2 diabetes is suggested to be attributable to weight gain 
implicated by hormones, neurotransmitters and neuro-
peptides that regulate appetite stimulation and conse-
quently increase food consumption (eg, leptin, histamine 
H1 receptor and melanocortin 4 receptor).16 Weight-in-
dependent insulin resistance and insulin secretion may 
also contribute to the association.16 Further potential 
physiological mechanisms are hypercortisolism, resulting 
from long-term activation of the hypothalamic–pituitary–
adrenal axis,18 changes in the immune function19 and 
inflammatory markers, such as elevated levels of inter-
leukin-6 and C reactive protein,20 altered levels of specific 
cytokines and chemokines21 and changes in the number 
and activation state of various leucocyte populations,21 all 
of which might impair glucose metabolism.
In sum, the number of systematic reviews and meta-anal-
yses is increasing but has applied different methodol-
ogies and thus has not led to a coherent overview on 
psychiatric disorders as risk factors for type 2 diabetes. A 
novel method for a higher level synthesis of evidence is 
the so-called ‘umbrella review’, also known as ‘review of 
reviews’. An umbrella review contributes to a comprehen-
sive overview and aims to compile all the evidence in a 
specific area. These field synopses have the ability to clarify 
what is still unknown and require future research.22 23 
Furthermore, umbrella reviews typically include a meth-
odological assessment of the included systematic reviews 
and meta-analyses, which contributes to a quality assess-
ment of the existing evidence.22 23 Obviously, the findings 
of umbrella reviews are dependent on the quality of the 
included systematic reviews and meta-analyses, which is 
an important methodological limitation.22 23
A recent umbrella review by Bellou and colleagues was 
the first of its kind to summarise risk factors for the devel-
opment of type 2 diabetes.24 A broad range of risk factors 
was explored, including specific biomarkers, dietary 
factors, lifestyle and environmental factors, as well as 
medical history, including psychiatric disorders. Although 
the umbrella review by Bellou and colleagues had a broad 
and general focus, it did not discuss psychiatric disorders 
or potential pathways in detail. A comprehensive umbrella 
review with focus on specific psychiatric disorders and 
potential pathways is therefore needed for a synthesis of 
the numerous systematic reviews and meta-analyses in this 
area. By clarifying the strengths and weaknesses of the 
existing evidence, an umbrella review will contribute to 
a more thorough understanding of the associations and 
potential underlying pathways and enhance the needs for 
future research. Our umbrella review will emphasise the 
methodological quality assessment of already conducted 
systematic reviews and meta-analyses.
ObjECtIvE
The aim of this umbrella review is to determine to 
what extent people with a psychiatric disorder have an 
increased risk of developing type 2 diabetes mellitus 
(compared with a reference group without psychiatric 
disorder). Furthermore, the umbrella review also aims to 
review evidence on mediating mechanisms.
MEthOds And AnAlysIs
This protocol was developed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses Protocols (PRISMA-P) guidelines (see online supple-
mentary file 1). In accordance with these guidelines, the 
present umbrella review protocol has been registered 
in the International Prospective Register of Systematic 
Reviews. Protocol amendments will be documented in 
PROSPERO. The procedure of the planned umbrella 
review is shown in figure 1.
Patient and public involvement
The patients or the public have not been involved in 
developing the present protocol nor will they be involved 
in conducting the umbrella review.
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search strategy
Database search
The following four electronic databases will be searched: 
PubMed (1966–present), Embase (1974–present), 
PsychINFO (1967–present) and the Cochrane Database 
of Systematic Reviews (1992–present). Furthermore, a 
manual screening of the reference lists of the included 
publications will be completed.
Search terms
In the four electronic databases, we will conduct a system-
atic search using search words and Medical Subject 
Headings (MeSH) terms combined using the Boolean 
logic operators (OR and AND). The search strategy will 
be based on three overall domains: psychiatric disorder, 
diabetes and systematic review/meta-analysis. Specific 
search words and MeSH terms within each domain will 
be combined using OR terms, and the domains will be 
combined by using AND terms. The domain of psychi-
atric disorders is coved by a comprehensive search 
string including terms and categories from the DSM-III 
or DSM-IV-TR (axis I and axis II)25 26 and the Interna-
tional Classification of Diseases, 10th Revision (ICD-
10), Classification of Mental Disorders (F00-F99).27 The 
search strategy has been generated in collaboration 
with a librarian and initially targeted PubMed, and will 
subsequently be adapted for the other databases. Date 
and language restrictions will not be used in the search 
strategy. Online supplementary file 2 shows the complete 
search string.
Eligibility criteria
Study design
The present umbrella review will include systematic 
reviews and meta-analyses of observational longitudinal 
studies in adult humans (≥18 years).
Inclusion and exclusion criteria
We set the following inclusion and exclusion criteria:
 ► The study is a full systematic review with or without 
a meta-analysis, describing both a systematic search 
string and eligibility criteria.
 ► The papers that will be included in the systematic 
review/meta-analysis describe observational longitu-
dinal studies in adult humans (≥18 years) and include 
results based on longitudinal data.
 ► Type 2 diabetes and diabetes in general is included 
as an outcome determined , for example,  by  a 
diagnosis, medical reports, medical prescription or 
self-reported measurement (It is estimated that more 
than 90 % of cases with diabetes mellitus have type 
2 diabetes.2 Therefore, we will include adult samples 
with 'diabetes in general, where no information is 
available on subtypes of diabetes' as we expect that 
the majority of the sample will actually have type 
2 diabetes. We are aware of potential bias and will 
discuss this accordingly). However, papers reporting 
only on type 1 diabetes, latent autoimmune diabetes 
in adults or maturity-onset diabetes of the young and 
other specific types of diabetes except type 2 diabetes 
will be excluded.
 ► Distinct psychiatric disorders are studied as a risk 
factor for type 2 diabetes. The presence of a psychi-
atric disorder at baseline can be determined, for 
example, by a diagnostic interview (ICD or DSM 
classifications), data from medical charts, registries, 
medication prescription as a proxy measurement 
or by self-reported psychiatric diagnoses or elevated 
levels of clusters of psychiatric symptoms (eg, ques-
tionnaires measuring psychiatric disorders).
 ► Inclusion of a group with psychiatric disorder and a 
control group without a psychiatric disorder at base-
line, all without having type two diabetes at baseline.
study selection
The study selection will be handled in EndNote and 
in the software programme Covidence; in 2015, Covi-
dence was selected by Cochrane to become the standard 
production platform for Cochrane Reviews.28 The initial 
search and the removal of duplicates will be performed 
by the first author. In all the identified publications, a 
screening of titles and abstracts for inclusion and exclu-
sion criteria will be carried out by two independent 
Figure 1 Flowchart of the umbrella review.
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reviewers. If eligibility of the publication is unsure, the 
publication will be identified as potentially relevant and 
will be enrolled in the next selection step. All publications 
identified as potentially relevant by at least one reviewer 
will be retrieved in full text and assessed for eligibility by 
two independent reviewers. In case of disagreement, the 
two reviewers will discuss this and, if necessary, a third 
reviewer will be included. Finally, the reference lists of the 
included publications are manually screened to identify 
publications, which fulfil the inclusion criteria. If both an 
original version and an updated version on a systematic 
review are identified, both papers will be included and 
discussed in the umbrella review. In the final umbrella 
review, a PRISMA flow diagram will show the selection 
flow and the number of included publications.
data extraction
The included systematic reviews and meta-analyses 
will be independently reviewed by two reviewers, and 
information will be extracted using a predesigned data 
extraction form. Any discrepancies will be discussed 
until consensus is achieved. If any included papers are 
published in a non-English language not spoken by the 
reviewers, Google Translate will be used and a translator 
will be contacted if needed. Extracted information will 
include first author, year of publication, type of study, 
risk factor(s), type of assessment of risk factor(s), assess-
ment of type 2 diabetes, the number of studies included, 
range of follow-up, total number of participants at base-
line without diabetes mellitus, gender distribution and 
range of age of cases/controls. Furthermore, the descrip-
tion of and primary conclusions about potential mecha-
nisms (eg, lifestyle behaviour and medication use) that 
link psychiatric disorders with diabetes risk will also be 
extracted. For meta-analyses, we will extract summary 
effect sizes (random effect size and/or fixed effect size, 
95% CI) and significance levels. When available, informa-
tion of between-study heterogeneity (Cochrane Q statistic 
or I2 and small-study effects will also be extracted.
Assessment of methodological quality
The methodological quality of each of the included 
systematic reviews and meta-analyses will be assessed 
independently by two reviewers using A MeaSurement 
Tool to Assess systematic Reviews,29 30 which consists of 
an 11-item checklist. Disagreements will be resolved by 
discussion. The assessment of methodological quality will 
be included in the discussion of the findings from the 
respective systematic reviews and meta-analyses.
dIsCussIOn
In the umbrella review, we will provide a high-level field 
synthesis and also discuss the results from the systematic 
reviews and meta-analyses for each psychiatric disorder as 
a potential risk factor for type 2 diabetes. Furthermore, 
mechanisms identified in the included systematic reviews 
and meta-analyses will be described and addressed. 
We will also focus on several methodological aspects, 
including the use of self-report versus diagnostic inter-
view and the differences among psychiatric diagnoses and 
clusters of psychiatric symptoms. Furthermore, the char-
acteristics of included primary studies in the systematic 
reviews and meta-analyses will be discussed. The results 
will be discussed in relation to the methodological quality 
assessment.
EthICs And dIssEMInAtIOn
According to Danish law, formal ethical approval is not 
required for the present study, as primary data will not be 
collected. For the same reason, the project does not have 
to be reported to the Danish Data Protection Agency. 
The umbrella review will be submitted for publication in 
a peer-reviewed journal using open access option, if avail-
able, and results will also be disseminated at international 
conferences.
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